Loading...
Despite the availability of safe and effective antihypertensive drugs, blood pressure is insufficiently controlled in many patients. Researchers are now exploring the feasibility of a vaccine targeting angiotensin II. In this study, conducted by the manufacturer, researchers in Switzerland and Germany randomly assigned 72 patients (average age, 52) with mild-to-moderate hypertension to receive three subcutaneous injections (at weeks 0, 4, and 12) of either 100 µg or 300 µg of CVT006-AngQb, a virus-like particle linked to the endogenous peptide angiotensin II, or placebo. Ambulatory blood pressure (ABP) was measured at baseline and 2 weeks after the last injection; plasma concentrations of antiangiotensin II antibody, activated complement fa…